Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 3197-44-2 | MDL No. : | MFCD11036292 |
Formula : | C6H13NO | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | PRAYXGYYVXRDDW-ZCFIWIBFSA-N |
M.W : | 115.17 | Pubchem ID : | 6950192 |
Synonyms : |
|
Num. heavy atoms : | 8 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 1.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 36.72 |
TPSA : | 32.26 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.99 cm/s |
Log Po/w (iLOGP) : | 1.61 |
Log Po/w (XLOGP3) : | 0.02 |
Log Po/w (WLOGP) : | -0.26 |
Log Po/w (MLOGP) : | 0.21 |
Log Po/w (SILICOS-IT) : | 0.96 |
Consensus Log Po/w : | 0.51 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -0.5 |
Solubility : | 36.4 mg/ml ; 0.316 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.25 |
Solubility : | 64.9 mg/ml ; 0.563 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -0.86 |
Solubility : | 15.8 mg/ml ; 0.137 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.56 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
65% | With hydrogen In ethyl acetate at 18 - 25℃; for 7 h; | Palladium on carbon (500 mg of 10percent) was added to a solution of benzyl (2R)-2-(hydroxymethyl)piperidine-1-carboxylate (5.00 g, 20.06 mmol) in ethyl acetate (70 ml) and the reaction mixture stirred at room temperature under an atmosphere of hydrogen for 4 hours. The mixture was filtered and a new portion of catalyst (300 mg) was added to the filtrate. The mixture was then stirred under an atmosphere of hydrogen for a further 3 hours. The mixture was filtered and the filtrate evaporated to leave a brown oil. The crude product was purified by kugelrohr distillation to give (2R)-piperidin-2-ylmethanol (1.51 g, 65percent yield):1H NMR (CDCl3): 3.53-3.48 (m, 1H), 3.36-3.31 (m, 1H), 3.02 (d, 1H), 2.61-2.53 (m, 2H), 2.35 (s, 2H), 1.75-1.73 (m, 1H), 1.56-1.47 (m, 2H), 1.40-1.25 (m, 2H), 1.14-1.03 (m, 1H |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With trifluoroacetic acid In dichloromethane at 20℃; for 1 h; | Trifluoroacetic acid (3 ml) was carefully added to a stirring solution of tert-butyl (2R)-2- (hydroxymethyl) PIPERIDINE-L-CARBOXYLATE (1.15 g, obtained as described in TETRAHEDRON, 5 8 (2002), 1343-1354) in DCM (3 ml) and stirred at room temperature for 1 hour. Volatiles were removed IN VACUO and the oil thus obtained dissolved in methanol (60 ml), and neutralized by addition of MP-Carbonate resin (polymer supported carbonate reagent ex. Argonaut Technologies Inc.) (approximately I g) whilst stirring at room temperature for 2 hours. The resin was filtered, washed with methanol (3 x 30 ml) and the filtrate concentrated. The resulting oil was dissolved in DCM (30 ml) and dried (MgSO4) before filtration and solvent removal to afford a grey oil (615 mg, 100percent); NMR spectrum (DMSO-D6) 1.44-1. 51 (m, 2H), 1.61 (m, 1H), 1.70-1. 78 (m, 3H), 2.84 (m, 1H), 3.03 (m, 1H), 3.21 (d, 1H), 3.49 (m, 1H), 3.57 (dd, 1H), 5.01 (bs, 1H), 7.65 (bs, 1H) ; Mass spectrum M+ 116. |
100% | With trifluoroacetic acid In dichloromethane at 20℃; for 1 h; | Trifluoroacetic acid (3 ml) was carefully added to a stirred solution of tert-butyl (2R)-2- (hydroxymethyl)piperidine-l-carboxylate (1.15 g, obtained as described in Tetrahedron, 58 (2002), 1343 - 1354) in DCM (3 ml). The reaction mixture was then stirred at room temperature for 1 hour. Volatiles were removed in vacuo and the oil thus obtained dissolved in methanol (60 ml), and neutralized by addition of MP-Carbonate resin (polymer supported carbonate reagent ex. Argonaut Technologies Inc.) (approximately Ig) whilst stirring at room temperature for 2 hours. The resin was filtered, washed with methanol (3 x 30 ml) and the filtrate concentrated. The resulting oil was dissolved in DCM (30 ml) and dried (MgSO4) before filtration and solvent removal to afford a grey oil (615 mg, 100percent); NMR spectrum 1.44 - 1.51 (m, 2H), 1.61 (m, IH), 1.70 - 1.78 (m, 3H), 2.84 (m, IH), 3.03 (m, IH), 3.21 (d, IH), 3.49 (m, IH), 3.57 (dd, IH), 5.01 (bs, IH), 7.65 (bs, IH); Mass spectrum M+ 116. |
100% | With trifluoroacetic acid In dichloromethane at 20℃; for 1 h; | The (2R)-piperidin-2-ylmethanol used as starting material was prepared as follows: Trifluoroacetic acid (3 ml) was carefully added to a stirring solution of tert-butyl (2R)-2- (hydroxymethyl)piperidine-l-carboxylate (1.15 g, obtained as described in Tetrahedron, 58 (2002), 1343 - 1354) in DCM (3 ml) and stirred at room temperature for 1 hour. Volatiles were removed in vacuo and the oil thus obtained dissolved in methanol (60 ml), and neutralized by addition of MP-Carbonate resin (polymer supported carbonate reagent ex. Argonaut Technologies Inc.) (approximately 1 g) whilst stirring at room temperature for 2 hours. The resin was filtered, washed with methanol (3 x 30 ml) and the filtrate concentrated. The resulting oil was dissolved in DCM (30 ml) and dried (MgSO4) before filtration and solvent removal to afford a grey oil (615 mg, 100percent); NMR spectrum 1.44 - 1.51 (m, 2H), 1.61 (m, IH), 1.70 - 1.78 (m, 3H), 2.84 (m, IH), 3.03 (m, IH), 3.21 (d, IH), 3.49 (m, IH), 3.57 (dd, IH), 5.01 (bs, IH), 7.65 (bs, IH): Mass spectrum M+ 116. |
[ 136030-04-1 ]
(S)-(1-Methylpiperidin-2-yl)methanol
Similarity: 0.93
[ 68474-13-5 ]
(R)-(1-Methylpiperidin-2-yl)methanol
Similarity: 0.93
[ 136030-04-1 ]
(S)-(1-Methylpiperidin-2-yl)methanol
Similarity: 0.93
[ 136030-04-1 ]
(S)-(1-Methylpiperidin-2-yl)methanol
Similarity: 0.93
[ 68474-13-5 ]
(R)-(1-Methylpiperidin-2-yl)methanol
Similarity: 0.93